Pre-treatment characteristics and outcome of patients treated with induction regimens containing HiDAC at M. D. Anderson Cancer Center refractory to one cycle of induction were compared with similar patients achieving a complete response (CR). Among 1597 patients treated with HiDAC-based induction from 1995 to 2009, 285 were refractory to one cycle. Median age was 59 years (range, 18 -85). Induction regimens included HiDAC with anthracyclines (n=181, 64%),
INTRODUCTION
The progress in the understanding of the biology of the neoplastic transformation in patients with acute myeloid leukemia (AML) has led to significant advances in the treatment of selected patients with well-defined cytogenetic and molecular characteristics. 1,2 However, current therapeutic strategies remain unsatisfactory for most patients, particularly those with adverse cytogenetic abnormalities and those with more advanced age. 3 The majority of younger patients and a significant proportion of older patients with AML achieve a complete remission (CR) after the initial induction regimen. However, relapse remains the major cause of failure and an obstacle to achieving long-term cure in most patients. 4 Several predictors of outcome for patients in first relapse have been identified and include the duration of the first CR, cytogenetics at diagnosis, age at relapse, and whether a prior allogeneic transplant was performed in first CR. 5 Among these, the length of first CR appears to be of major significance. 5, 6 Primary refractory disease, variably defined as failing to achieve a CR after one or two cycles of standard combination chemotherapy, accounts for a significant proportion of patients with expected poor long-term outcome. As inherent in the definition, patients with primary refractory AML have leukemic cells which are primarily resistant to the effects of cytotoxic, DNA-interactive chemotherapy and as such would be candidates for investigational strategies focused on alternative cytostatic or cytotoxic mechanisms. Those at the highest risk of induction failure include patients with adverse karyotype, therapy-induced AML, and AML For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From evolving from other hematological disease such as myelodysplastic syndrome or myeloproliferative disorders. 4 Standard treatment of AML has included the combination of standard dose ara-C (100 or 200 mg/m 2 daily for 7 days) and an anthracycline, variably daunorubicin or idarubicin. Recent studies have suggested a significant benefit for escalation of dose of the anthracycline in particular subsets, both in the younger and older adults. 7, 8 Few studies have examined the role of escalating the dose of ara-C in induction. A meta-analysis of these studies concluded that induction therapy with HiDAC improved long-term disease control and overall survival in adults younger than 60 years. 9 Therefore, some centers, including ours, have adopted this strategy for the frontline therapy of younger patients and have reported high CR rates of 70-80% in prior trials employing this strategy.
Clearly, failing to respond to such regimens with high dose anthracyclines or HiDAC is likely to have different prognostic implications than failing to achieve CR after the more traditional, less intensive regimens. Information on patients who are refractory to such HiDAC-based induction is limited. We therefore undertook this study to examine the characteristics and outcome of patients with AML who failed to achieve CR after one cycle of such HiDAC-based regimen.
We chose to exclude patients achieving CR without platelet recovery (CRp) and PR as well as those who received more than 1 course of HiDAC-based induction.
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MATERIALS AND METHODS

Patients
Between January 1995 and June 2009, a total of 1597 patients with AML were treated with a HiDAC (defined as Table 1) . The characteristics of patients with primary refractory disease and those who achieved CR after 1 course of induction are summarized in Table 2 . The median age of these patients was 57 years (range, 17 -88 years). Their median presenting white blood cell count (WBC) and platelet counts were 6.8 x 10 9 (range, 6.3 -394 x 10 9 /l) and 51 x 10 9 /l (range, 3-1355 x 10 9 /l), respectively. Cytogenetics (assessed based on the criteria published by the Hereon, we will focus on the 1179 patients who either achieved a CR or were refractory to 1 induction course. Not included in this analysis were 129 patients who received more than 1 course (2 or 3 courses) of HiDAC-based chemotherapy; 38 achieved CR and 3 CRp, with 63 patients remaining resistant, and 25 dying during the induction courses.
Treatment regimens
Various frontline regimens were used during the specified period (Table 3) .
They included regimens combining HiDAC with anthracyclines in 765 patients (65%), and HiDAC with non anthracycline chemotherapy (including fludarabine, clofarabine, topotecan, and/or troxacitabine) in 414 patients (35%) The dose of ara-C in all these regimens was 1-2 g/m 2 daily for 3-5 days with each dose given over 2-3 hours. Standard supportive practices, prevailing at the time of inclusion, such as prophylactic and therapeutic antibiotics, and transfusion of blood products were used to support the patients during the aplastic phase.
Response Criteria and Statistical method
CR was defined by the presence of less than 5% blasts in the bone marrow (BM) with more than 1x10 9 /l neutrophils and more than 100x10 9 /l platelets in the peripheral blood (PB). Patients with CRp achieved the above criteria with the exception of the platelet count remaining less than 100 x 10 9 /l. PR was defined as achieving CR criteria in the peripheral blood with bone marrow blast reduction by ≥ 50% but remaining >5%. 11 For personal use only. on November 16, 2017. by guest www.bloodjournal.org A P-value of less then 0.05 was considered to be significant.
RESULTS
Characteristics of patients with primary refractory disease
Among the patients with AML treated with a HiDAC containing regimens, 285 (19%) were refractory to the first cycle of induction. Patients with primary refractory disease were older (median age, 59 vs. 56 years) than those who achieved CR (p<0.001). They also had a higher presenting WBC and a lower presenting platelet count (p values 0.04 and 0.02, respectively)( Table 2) . Patients with primary refractory disease were also more likely to have had antecedent hematological disease and unfavorable cytogenetics (p values of < 0.001 for For personal use only. on November 16, 2017. by guest www.bloodjournal.org From both). Furthermore, they were more likely to have therapy-related AML than the responding patients (p=0.03). Interestingly, among the patients with available FLT3 mutational status, there was no difference between the primary refractory patients and those achieving a CR (P=0.85). There was also no difference by the induction regimen between these two groups when considering the combination of HiDAC with an anthracycline compared with HiDAC and a non-anthracycline agent (p=0.58, table 4). On multivariate analysis, unfavorable cytogenetics, older age (≥ 50 years), severe thrombocytopenia (< 30 x 10 9 /L), and antecedent hematological disease were predictive of lack of response to first cycle of induction therapy (data not shown). Mutated FLT3 did not predict for a lower likelihood of response; this is consistent with prior observational reports suggesting no influence of FLT3 mutational status on achievement of CR. 12
Response and survival outcome in patients with primary refractory disease
Among the 285 patients with primary refractory disease after the first cycle of induction, 197 (69%) received salvage therapy which included combination chemotherapy in 111 (39%) with or without ara-C, single agent therapy such as hypomethylating agents in 63 (22%), or allogeneic stem cell transplant (without further chemotherapy prior to transplant) in 23 (8%) ( (Table 7 ). Of note, there was a selection bias for the patients proceeding directly to an allogeneic stem cell transplant with a significantly lower blast % in these patients (p=0.02).
The median survival of the 285 patients with primary refractory disease is 3.8 months (Figure 1a ). The median CR duration for the 35 patients who achieved CR is 9.1 months ( Figure 2 ). As expected, the outcome of these patients was significantly better than those who did not achieve a CR, with a median survival of 19 months vs. 6 months, respectively (excluding patients who died within 2 months from the first salvage therapy, Figure 2 ). Severe thrombocytopenia, leukocytosis, and increasing marrow blast % at salvage, as well as unfavorable cytogenetic, and salvage not including allogeneic stem cell transplant were associated with a significantly worse survival (all p values < 0.05, Table 6 ). Multivariate stepwise analysis identified platelet count of < 30 x 10 9 /L at salvage (p = 0.001), WBC ≥ 10 x 10 9 /L at salvage (P = 0.007), increasing marrow blast percentage at salvage (p < 0.001), and unfavorable cytogenetics at presentation (p<0.001) as significant for survival (Table 7) . Salvage strategies did not independently affect overall survival after adjustment for the other 
DISCUSSION
Relapse is the most important obstacle to achieving long-term cure in patients with AML. Prognostic factors for patients with relapsed AML include age at relapse, cytogenetics at diagnosis, and the duration of the first CR. 5, 6 The latter has been shown in several studies to be the most important parameter to predict achievement of second CR, and subsequently disease-free and overall survival. 5, 6 At extreme is primary refractory AML when CR was never achieved.
As such, these patients are expected to have a dismal prognosis. However, prior reports have shown that a proportion of these patients can be salvaged with regimens containing HiDAC when standard dose ara-C was used for induction. 13 Here we examined the outcome of patients who received HiDAC as a component of their induction regimen and were refractory to it. Only 35 (18%) of patients achieved a CR with a median CR duration of 9 months; another 8 (4%) achieved CRp for an overall response rate of 22%. Unfavorable cytogenetics at presentation, presence of antecedent hematological disorder, and salvage treatment with non-transplant strategies were associated with a worse CR rate.
Clearly the potential for salvaging patients who are refractory to one cycle of HiDAC based induction is limited and only about a quarter of these patients can be rescued with the available salvage strategies. Further studies to identify biological factors responsible for lack of response to the standard cytotoxic regimens and to develop and design new agents and strategies to overcome such resistance are needed. It is interesting to note that patients who proceeded directly to an allogeneic stem cell transplant had an improved survival on univariate but not multivariate analysis suggesting a selection bias which is confirmed by the significantly lower marrow blast percentage in transplanted patients (P=0.002).
Historically, the definition of primary refractory AML has not been uniform due to the different interpretations of the definition of CR and the number of cycles and type of chemotherapy needed to achieve it. With the evolution of the definition of CR and the more recent recognition of subtleties in defining a morphological CR such as the role of persisting circulating blasts despite achievement of less than 5% marrow blast, 14 and the importance of normalization of peripheral blood counts, 15 it has become easier to arrive at uniform and universal definitions of failure of induction therapy. 11 It is clear that failure based on persistence of more than 50% blasts in the marrow is different from failing to meet the definition of CR due to the presence of few circulating blasts or persistent thrombocytopenia. 14, 15 The exact time to assess response after the induction course has not been standardized. Traditionally, it has been customary by many groups to perform a bone marrow exam on days 10-14 or days 21-28 to For personal use only. on November 16, 2017. by guest www.bloodjournal.org From assess for the presence of residual leukemia after the induction chemotherapy and arbitrary definitions have been used to determine the need for a second induction course depending on the persistence of leukemic cells at these time points. However, the lack of uniformity and the absence of certainty on the percentage of blasts that is clearly indicative of disease resistance, make these determinations less than ideal. Many patients with residual marrow blasts on a day 14 marrow achieve a CR although the probability of this decreases with increasing blast percentage. 16 Similarly, whether patients should fail at least 2 cycles of chemotherapy before being considered as primary failure is debatable but it is generally accepted that patients who have failed only one cycle of standard dose chemotherapy will do better than those who have not responded to 2 or more cycles. In fact, a reduction of bone marrow blasts to 5-15% (or a partial response -PR) after the first cycle is associated with a high chance of achieving CR after a second course of chemotherapy. 17 Although, in this study, the overall survival was inferior for the patients with PR, there was no difference in relapse rate in patients achieving CR after the first or second course. 17 Thus, although other studies have not demonstrated such a likelihood of a better outcome for the patients achieving PR after the first cycle than for those with primary refractory disease, the mere possibility of achieving a CR with the second course of chemotherapy further mandates having a more uniform definition of primary refractory disease. This is particularly important as the second course in many patients may include higher doses of ara-C (defined arbitrarily as ≥ 1g/m 2 per dose) in patients who received standard dose ara-C for their induction. Regimens containing high dose ara-C (HiDAC) are generally considered as the best salvage option for patients with primary refractory disease or those with a short first CR. 13 Using more traditional regimens containing lower doses of ara-C it may be possible to have a better outcome if the patients destined to be unresponsive are identified early (e.g. by a day 14 bone marrow) and treated with a second similar course of induction. Rowe et al have recently reported that among patients with AML treated in six studies by the Eastern Cooperative Oncology Group (ECOG), those who achieved a CR after one or two courses of chemotherapy had a similar outcome. 18 This further illustrates the need to standardize the definition of primary refractory disease as clearly lack of response to a single course of standard dose ara-C cannot be equated to unresponsiveness to HiDAC containing induction regimens with different prognostic implications for the two scenarios. This study has the limitations associated with retrospective studies.
However, the use of HiDAC-based regimen for treating the vast majority of patients with AML (75%) treated during the study period, reduces the likelihood of selection biases. Further prospective studies comparing HiDAC and standarddose ara-C regimens and the role of one or two cycles of induction may shed further light to the outcome of these patients. 
